IRVINE, Calif.--(BUSINESS WIRE)--Dec. 18, 2015--
Masimo
(NASDAQ: MASI), the global innovator of noninvasive patient monitoring
technologies, announced today that it will increase investment in
infrastructure and research and development in response to the
moratorium on the Medical Device Tax.
For years, the United States has led the world in life-saving medical
innovations. Unfortunately, the Medical Device Tax of 2013 became an
impediment to innovation that springs from start-ups, and many
established companies curtailed their investments in research and
development and reduced their workforces to pay the new revenue tax.
“We applaud the bipartisan efforts of Congress and the administration to
suspend the medical device tax for two years,” said Joe Kiani, Chairman
and CEO of Masimo. “This two-year moratorium will allow us to
immediately begin to increase our investment in our infrastructure and
research and development.”
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. The benefits of Masimo SET®
have been proven in more than 100 independent and objective
studies and it is estimated to be used on more than 100 million patients
in leading hospitals and other healthcare settings around the world. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVI®) and Oxygen
Reserve Index (ORI™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive open architecture patient monitoring and connectivity platform
designed to speed the pace of innovation and reduce the cost of care.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the
MightySat™ fingertip pulse oximeter. Additional information
about Masimo and its products may be found at www.masimo.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151218006075/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com